Overview
FXT research is based upon a strategy that exploits functional screening to develop new classes of drugs with novel mechanisms of action
Rapid and efficient identification of proteins and peptides with therapeutic potential by functional screening is coupled with proprietary methods of generating small molecule pharmaceuticals that mimic the function of these lead proteins and peptides.
To date this strategy has led to the discovery of Broad Spectrum Chemokine Inhibitors (BSCIs), which are a novel class of anti-inflammatory agents acting through inhibition of inflammatory cell migration, and of Apolipoprotein-E mimetics, which are a novel class of small molecules that can stimulate the clearance of cell debris with applications in inflammation but also other disease areas. Our G-protein coupled receptors Agonist-Enriched Libraries (GAEL) is an enabling platform technology for functional screening.